Home > Cardiology > AHA 2022 > Letter from the Editor

Letter from the Editor

Prof. Marc Bonaca, University of Colorado, USA
AHA 2022
Dear Colleagues,

Thank you for your interest in this edition of Medicom’s Conference Report covering the American Heart Association’s 2022 Scientific Sessions in Chicago, USA. This year’s meeting was filled with late-breaking clinical trials, innovative science, and therapeutic device applications for heart failure patients.

This year’s AHA meeting covered a breadth of topics. In the following pages you will read about new data for patients with heart failure including diuretic choice, iron repletion, and benefits of intensive titration of proven therapies; novel approaches to hypertension including endothelin antagonism, renal denervation, and mindfulness; results from the long-awaited BEST-CLI trial asking what the best first approach is to revascularization in patients with critical limb-threatening ischemia; and novel approaches to patients with arrythmia. Late-breaking data were presented on the use of SGLT2 inhibitors in patients with chronic kidney disease; evaluating novel and existing lipid modifying therapies, testing novel digital therapeutics for diabetes, and therapies to reduce risk in outpatients with COVID-19.

The summaries provided are intended to give an overview of the science with references to facilitate further learnings. All are written independently and are peer-reviewed for balance. We hope you find this edition informative, engaging, and balanced and thank you again for your readership.


Marc P. Bonaca MD MPH




Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.

Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training, he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.

Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.

Conflict of Interest Statement:

Grant support to BWH from AstraZeneca, MedImmune, Merck, PfizerGrant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi

Posted on